673 Metabolomic profiling of cutaneous lupus erythematous

Cutaneous lupus erythematosus (CLE) is a chronic autoimmune disease that disproportionately impacts patients with skin of color. Metabolic reprogramming plays critical role in modulating the innate and adaptive immune response, but its cutaneous conditions, like CLE, less well studied. Thus, untargeted liquid chromatography-mass spectrometry metabolomics was performed to characterize serum CLE patients. Eleven (8 Black 2 Hispanic Whites) 14 normal controls were recruited from outpatient dermatology clinics at University Texas Southwestern Medical Center Parkland Health Hospital System Dallas, TX. Unpaired t-tests compare samples controls. Fourteen (9 vs. 6 control) 13 (5 8 analyzed. found have 11 metabolites differential abundance only serum. showed increased levels citrulline (fold change (FC)=1.15, p=0.02) uracil (FC=1.79, p=0.04), down-regulation cyclic adenosine diphosphate (cADP) (FC=0.83, nicotinamide mononucleotide (NMN) (FC=0.75, p=0.016), adenine dinucleotide (NAD+) (FC=0.86, p=0.016). Confirmatory qRT-PCR assays for enzymes involved NMN NAD+ metabolism, CD38 NT5E. (mean FC=26.94) NT5E FC=7.84) be significantly upregulated 5 biopsies, which support decreased skin. These findings suggest abnormalities metabolism may novel biomarker treatment implications.